AC IMMUNE SA

ACIU represents Acer Therapeutics Inc., a pharmaceutical company focused on acquiring, developing, and commercializing therapies for patients with serious rare and ultra-rare diseases. The company's pipeline includes product candidates targeting conditions with few or no approved treatment options. ACIU is listed on the Nasdaq Capital Market under the ticker symbol ACIU. For the latest corporate updates and pipeline developments, refer to the company's investor relations materials and the stock data displayed on this page.

The current price of ACIU stock fluctuates throughout the trading day based on supply and demand, so it is not fixed here. To see the latest price, check the real-time quote displayed at the top of this page. That figure reflects the most recent trade and may differ from the previous close. For historical closing prices, consult the price chart and historical data sections available on this page.

Evaluating ACIU's valuation involves reviewing metrics such as price-to-earnings, price-to-sales, and enterprise value, though clinical-stage biopharmaceutical companies often have limited or no revenue, making traditional earnings-based ratios less meaningful. Investors may instead focus on cash position, pipeline progress, and potential market opportunities. Because ACIU's financial profile can change with trial results or regulatory news, use the latest valuation and financial data shown on this page for a current assessment.

ACIU may be eligible for trading in pre-market and after-hours sessions, depending on your brokerage and the venue. These extended sessions typically have lower liquidity, wider spreads, and higher volatility than regular hours. Not all brokers offer extended-hours trading for every security. To confirm availability and current extended-hours quotes, check your trading platform and the market data displayed on this page.

Key risks for ACIU include clinical trial failures, regulatory delays or rejections, limited revenue, and the need for additional financing, which can dilute existing shareholders. As a small-cap biopharmaceutical company, its stock may be volatile and sensitive to pipeline news, trial data, and broader market conditions. Competition, intellectual property challenges, and manufacturing or supply issues can also affect results. Review ACIU's risk factors in its SEC filings for a comprehensive discussion.

Earnings information for ACIU is available through the company's quarterly and annual reports filed with the SEC, as well as its investor relations website. These filings include financial statements, management discussion, and business updates. Many financial data platforms also summarize earnings dates, revenue, and net income. For the most recent reported figures, refer to the earnings section on this page or the company's official disclosures.